Adjuvant immunotherapy instead of adjuvant chemotherapy in the high-risk situation for recurrence in adenocarcinomas of the stomach and esophagogastric junction: results of the VESTIGE study

2026-03-01

0

PRE

AI

DOI：10.1007/s00104-026-02479-0

Original

Original request for help

Share

Save